Reply to: "Comment on 'Bullous pemphigoid after anti-PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes'"
J Am Acad Dermatol. 2022 Dec;87(6):e245-e248.
doi: 10.1016/j.jaad.2020.05.023.
Epub 2020 May 15.
1 Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Cutaneous Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
2 Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
3 Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
4 Department of Cutaneous Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
5 Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
6 Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Cutaneous Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Electronic address: [email protected].